Presentation is loading. Please wait.

Presentation is loading. Please wait.

The CDRH Software Message (October 19, 2002) John F Murray Jr.. Center for Devices & Radiological Health US Food and Drug Administration

Published byRuby Stewart Modified over 8 years ago

Similar presentations

Presentation on theme: "The CDRH Software Message (October 19, 2002) John F Murray Jr.. Center for Devices & Radiological Health US Food and Drug Administration"— Presentation transcript:

1 The CDRH Software Message (October 19, 2002) John F Murray Jr.. Center for Devices & Radiological Health US Food and Drug Administration JFM@CDRH.FDA.GOV

2 Mr. John F Murray Jr. Mr. Murray currently serves as the: –Software and Part 11 Compliance Expert –Office of Compliance –Center for Devices and Radiological Health (CDRH) –US Food and Drug Administration.

3 Mr. John F Murray Jr. In this position Mr. Murray is the primary advisor to the Director of the Office of Compliance in the areas of: –Software validation –Software policy –Software classification and –Part 11 compliance issues. He is also responsible for: –the software standards program and –the software engineering training program at CDRH.

4 Mr. John F Murray Jr. Mr. John F Murray Jr. joined the FDA in March 1994. Prior to becoming an FDA staffer, he was: –A qualified Reactor Operator with United States Navy Submarine Fleet –A Computer Field Engineer with Telex Computer Products –An Electronics and Software Engineer with The General Dynamics Corporation and a –Systems Engineer at Technology Management & Analysis

5 Mr. John F Murray Jr. Prior to joining the Office of Compliance in June 2001, Mr. Murray served as the Team Leader for Software and Intelligent Medical Devices with the United States Food and Drug Administration, Rockville, MD. Mr. Murray is the primary Advisor to the Chief of the Medical Electronics Branch in the areas of software engineering, software safety and software standards.

6 Mr. John F Murray Jr. The software team is responsible for: –Maintaining the technical foundations that are required for the regulation of medical device software. –Regulatory decisions regarding the safety and effectiveness of medical device software are based on engineering and scientific foundations. –Software Standards is one example of these engineering foundations.

7 Mr. John F Murray Jr. Mr. Murray is chairperson for the FDA Software Standards Technical Group (STG). –The Software STG is responsible for review and recognition of software engineering standards for use in the regulatory process. Mr. Murray also serves as Co-Chair of the AAMI Software Committee.

8 Mr. John F Murray Jr. Mr. Murray earned a: –BS Degree in Electrical Engineering from George Mason University –MS Degree in Computer Science from Rensselaer Polytechnic University (RPI).

9 The CDRH Software Message John F Murray Jr.. Center for Devices & Radiological Health US Food and Drug Administration JFM@CDRH.FDA.GOV

10 Public Health and Software The Quality of Pubic Health is highly dependent on the Quality of Medical Software i.e. Medical Device Software, Clinical Information Systems, Hospital Information Systems, Manufacturing Systems etc

11 What type of Quality do we Want? To get some perspective lets try what I call the YB scale. [yugo vs. bmw] I ask the following questions: Where would Microsoft be on this scale? Where do we want our software quality to be? Where do you want your software to be?

12 Do the regulations recognize this need Yes they do: 21 CFR 820.30 21 CFR 820.30 (a) (2) (i) 21 CFR 820.30 (g) 21 CFR 820.70 (i)

13 21 CFR 820.30 Design Controls Each manufacturer of any Class II or Class III device, and the Class I devices listed in paragraph (a)(2) of this section, shall establish and maintain procedures to control the design of the device in order to ensure that the specified design requirements are meet.

14 21 CFR 820.30 (a)(2)(i) Class I –The following Class I devices are subject to design controls: Devices automated with computer software

15 21 CFR 820.30 (g) Design validation shall include software validation and risk analysis where appropriate

16 21 CFR 820.70 (i) Automated processes –When computers or automated data processing systems are used as part of production or the quality system, the manufacturer shall validate computer software for its intended use according to an established protocol. All software changes shall be validated before approval and issuance. These validation activities shall be documented.

17 Software is Different Traditionally not engineered, but crafted Not physics based Easy to change or is it? Does not fail the hardware way. etc

18 What is the goal? By Law: Medical Devices must be reasonably safe and effective By default: Software must be safe and effective

19 Safe and Effective It depends! Cannot be easily defined What is safe and effective software –Software Engineering –Risk Management –Quality System

20 Conclusion The law and regulations are written in broad terms Software should be engineered using: –Software Engineering –Risk Management –Quality System This is the CDRH Software Message

21 Keys to Success Avoid denial Make a plan Document your activities Remember the three A’s of meeting the regulatory requirement –Activities –Attributes –Artifacts

Download ppt "The CDRH Software Message (October 19, 2002) John F Murray Jr.. Center for Devices & Radiological Health US Food and Drug Administration"

Similar presentations

The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.

The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
VALIDATION OF COMPUTERISED SYSTEMS IN THE PHARMACEUTICAL INDUSTRY Matt Safi Product manager.

VALIDATION OF COMPUTERISED SYSTEMS IN THE PHARMACEUTICAL INDUSTRY Matt Safi Product manager.
Determining the Regulatory Pathway to Market Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
Www.bsee.gov Subpart S - SEMS September 11, 2012 Prepared by: BSEE, Office of Safety Management Author: Jason Mathews.

Subpart S - SEMS September 11, 2012 Prepared by: BSEE, Office of Safety Management Author: Jason Mathews.
Regulatory Compliant Performance Improvement for Pharmaceutical Plants AIChE New Jersey Section 01/13/2004 Murugan Govindasamy Pfizer Inc.

Regulatory Compliant Performance Improvement for Pharmaceutical Plants AIChE New Jersey Section 01/13/2004 Murugan Govindasamy Pfizer Inc.
Introduction to Regulation

Introduction to Regulation
Becker Grand Rounds: Wally Pellerite June 30, 2011.

Becker Grand Rounds: Wally Pellerite June 30, 2011.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.

Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
Telemedicine Credentialing and Privileging October 16, 2014.

Telemedicine Credentialing and Privileging October 16, 2014.
1. 2 This tool focuses on the CSBG requirements relating to tripartite board composition and selection and is divided into the following four parts: 1.General.

1. 2 This tool focuses on the CSBG requirements relating to tripartite board composition and selection and is divided into the following four parts: 1.General.
FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.

FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.
CDRH Software Regulation

CDRH Software Regulation
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.

Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
Animal Feed GRAS Notifications Geoffrey K. Wong, M.S. Division of Animal Feeds Center for Veterinary Medicine Pet Food Institute Pet Food Institute October.

Animal Feed GRAS Notifications Geoffrey K. Wong, M.S. Division of Animal Feeds Center for Veterinary Medicine Pet Food Institute Pet Food Institute October.
Center for Devices and Radiological Health U. S. Department of Health and Human Services Al Taylor Acting Chief, Medical Electronics Branch Office of Science.

Center for Devices and Radiological Health U. S. Department of Health and Human Services Al Taylor Acting Chief, Medical Electronics Branch Office of Science.
FDA Resources and Meetings FDA/EMA Orphan Designation and Grant Workshop Silver Spring, Maryland FDA Campus (White Oak) October 12, 2012 Bill Sutton Deputy.

FDA Resources and Meetings FDA/EMA Orphan Designation and Grant Workshop Silver Spring, Maryland FDA Campus (White Oak) October 12, 2012 Bill Sutton Deputy.
21 CFR Part 11 A Food Industry Perspective FDA Public Meeting June 11, 2004 Sia Economides Center Director Center for Development of Research Policy and.

21 CFR Part 11 A Food Industry Perspective FDA Public Meeting June 11, 2004 Sia Economides Center Director Center for Development of Research Policy and.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.

FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)

Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)
Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.

Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.

Similar presentations

Ads by Google